Medical News Podcast

This episode reviews randomized-trial analyses of antidepressant-related QTc changes and early cardiovascular events; an observational study of buprenorphine initiation during concurrent alcohol and opioid withdrawal; and a target-trial emulation examining renal outcomes with SGLT2 inhibitors and GLP-1 receptor agonists according to albuminuria status.

Drs. Martinez and Montesi discuss how to personalize treatment for ILD, particularly IPF. They explain that current personalization is largely driven by side effects, insurance constraints, and patient preferences, emphasizing the need to move toward biomarker- and imaging-guided, pathway-based therapies and innovative clinical trial designs (eg, cohort enrichment and platform trials) similar to oncology.

Drs. Lio and Yosipovitch discuss that while biologic therapy has greatly improved atopic dermatitis control, many patients still struggle with residual itch, sleep disruption, and intermittent flares that impact daily life. They explain how layering proactive topical treatments, over-the-counter skincare, antipruritic measures, and behavioral strategies onto biologics can preempt flares, relieve itch, and significantly improve quality of life.

This episode covers the Jehovah’s Witness policy change making acceptance of donor blood components an individual conscience decision; a study associating short oral steroid courses with serious adverse events in adults with type 2 diabetes; and a scoping review documenting sex differences in medical treatment.

This episode reviews a randomized phase 3 trial suggesting that loberamisal may improve functional recovery following acute ischemic stroke; a SELECT trial analysis examining the efficacy and safety of semaglutide across different levels of frailty; and a CDC investigation of deaths and serious adverse events following ceftriaxone injections that highlights how severe anaphylaxis can occur without classic skin findings.

Drs. Scarfò and Ghia discuss how CLL creates a delicate balance between blood clots and bleeding, a challenge made more complex by BTK inhibitors and common comorbidities in older patients. They explore how careful risk assessment, thoughtful use of anticoagulants, and close patient communication are essential to keep treatment both effective and safe.

This episode reviews updated AAP recommendations for RSV prevention in infants and high-risk children entering a second RSV season, phase 3 data suggesting TP53 mutation status may help identify patients with EGFR-mutated advanced non–small cell lung cancer who benefit from adding chemotherapy to osimertinib, and results from two phase 3 trials showing that the IL-33–targeting biologic tozorakimab reduced COPD exacerbations in patients who remained at risk despite standard inhaled therapy.

Drs. Owens and de Feria review emerging data on epicardial adipose tissue and MRI-based markers to refine hypertrophic cardiomyopathy risk assessment. They highlight integrating imaging and biomarkers, including NT‑proBNP, to predict heart failure and arrhythmic outcomes.

Drs. Kittleson and Ghafourian discuss how to accurately diagnose ATTR-CM, emphasizing that the first step must always be a complete monoclonal protein screen to exclude AL amyloidosis before interpreting a PYP scan. They highlight common pitfalls with PYP imaging; the supportive (but not definitive) role of cardiac MRI; the need for routine TTR genotyping after diagnosis; and the importance of recognizing noncardiac clues to identify patients early enough to benefit from disease‑modifying therapies.

Drs. Chase and Griffiths discuss how to choose biologic therapies for allergic asthma using a personalized approach based on biomarkers, asthma severity, comorbid type 2 diseases, and practical factors (eg, dosing and access). They highlight the importance of reducing steroid use, educating patients about biologics, and continually reassessing treatment to improve control and quality of life.